{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:21Z","timestamp":1790692221821,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400773"],"award-info":[{"award-number":["32400773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201181","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:49:48Z","timestamp":1773852588000},"page":"201181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor T cell targeting CD44E variant in HCC holds therapeutic potential"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5155-9232","authenticated-orcid":false,"given":"Rui","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Ka Wing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piaorong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-9189","authenticated-orcid":false,"given":"Nathalie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201181_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2026.201181_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.omton.2026.201181_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omton.2026.201181_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201181_bib5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201181_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201181_bib7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/leu.2017.249","article-title":"Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells","volume":"32","author":"Lai","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201181_bib8","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201181_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201181_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2016.01.029","article-title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing","volume":"164","author":"Yang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201181_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100728","article-title":"The role of alternative splicing in cancer: From oncogenesis to drug resistance","volume":"53","author":"Sciarrillo","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.omton.2026.201181_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/hep.30500","article-title":"Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms","volume":"70","author":"Chen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.omton.2026.201181_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7150\/ntno.62639","article-title":"Development of CD44E\/s dual-targeting DNA aptamer as nanoprobe to deliver treatment in hepatocellular carcinoma","volume":"6","author":"Lo","year":"2022","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.omton.2026.201181_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","author":"Z\u00f6ller","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201181_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/biom11121850","article-title":"CD44: A Multifunctional Mediator of Cancer Progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omton.2026.201181_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201181_bib17","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/0008-5472.CAN-13-2309","article-title":"CD44v8-10 is a cancer-specific marker for gastric cancer stem cells","volume":"74","author":"Lau","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201181_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2195363","article-title":"The v8-10 variant isoform of CD44 is selectively expressed in the normal human colonic stem cell niche and frequently is overexpressed in colon carcinomas during tumor development","volume":"24","author":"Boman","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.omton.2026.201181_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102588","article-title":"Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis","volume":"298","author":"Guo","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201181_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3892\/ijmm_00000279","article-title":"Frequent expression of the high molecular, 673-bp CD44v3,v8-10 variant in colorectal adenomas and carcinomas","volume":"24","author":"Kopp","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.omton.2026.201181_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1398-9995.1997.tb01031.x","article-title":"Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions","volume":"52","author":"Werfel","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.omton.2026.201181_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","article-title":"Next-generation cancer organoids","volume":"21","author":"LeSavage","year":"2022","journal-title":"Nat. Mater."},{"key":"10.1016\/j.omton.2026.201181_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12935-024-03272-x","article-title":"Application status and optimization suggestions of tumor organoids and CAR-T cell co-culture models","volume":"24","author":"Ning","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omton.2026.201181_bib24","first-page":"690","article-title":"Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201181_bib25","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201181_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.omton.2026.201181_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108387","article-title":"Immunotherapy for hepatocellular carcinoma: Recent advances and future targets","volume":"244","author":"Yu","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2026.201181_bib28","article-title":"CD44: a cancer stem cell marker and therapeutic target in leukemia treatment","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201181_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201181_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201181_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051050","article-title":"CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus","volume":"13","author":"Textor","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201181_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201181_bib33","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201181_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201181_bib35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.omton.2026.201181_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.omton.2026.201181_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201181_bib38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omton.2026.201181_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omton.2026.201181_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omton.2026.201181_bib41","article-title":"Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer","volume":"7","author":"Wong","year":"2025","journal-title":"JHEP Rep."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:22:32Z","timestamp":1783326152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000573"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201181","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T cell targeting CD44E variant in HCC holds therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201181"}}